

Table S4. Total ICU costs in patients with observed data available from all three time points, without any censoring or data imputations, in the pooled data analysis (S5).

Mean (SD)		Difference in means, €	Median (IQR)		Difference in medians, €
dexmedetomidine (n = 366)	standard care (n = 361)		dexmedetomidine (n = 366)	standard care (n = 361)	
14,983 (12,782)	18,196 (15,349)	-3,213	10,362 (6,736-8,954)	12,284 (7,557-23,821)	-2,462

Table S5. Total ICU costs with dexmedetomidine and current standard care sedatives in the 18 centers whose routine daily ICU cost information the unit cost assumptions in this work were based on (S6). These 18 study sites included a total of 339 patients in the 2 trials (34% of pooled total N). 36% of these participated in the MIDEX trial, 64% in the PRODEX trial. Most of these patients were treated at trial centers in Finland and Switzerland (195 and 66, respectively).

Mean (SD)		Difference in means, €	Median (IQR)		Difference in medians, €
dexmedetomidine (n = 171)	standard care (n = 168)		dexmedetomidine (n = 171)	standard care (n = 168)	
17,076 (18,003)	18,869 (16,622)	-1,793	9,588 (6,539 - 20,702)	14,125 (7,468 - 24,672)	-4,567